CN102458156A - Health food or pharmaceutical composition comprising chestnut shell extract - Google Patents

Health food or pharmaceutical composition comprising chestnut shell extract Download PDF

Info

Publication number
CN102458156A
CN102458156A CN2010800359033A CN201080035903A CN102458156A CN 102458156 A CN102458156 A CN 102458156A CN 2010800359033 A CN2010800359033 A CN 2010800359033A CN 201080035903 A CN201080035903 A CN 201080035903A CN 102458156 A CN102458156 A CN 102458156A
Authority
CN
China
Prior art keywords
chestnut
skin
pharmaceutical compositions
healthy food
bark extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800359033A
Other languages
Chinese (zh)
Inventor
沈范
金善暎
金赫
高在濚
尹侦训
徐姃我
尹晙源
林庆珉
朱泳協
朴永镐
李昌锡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority to CN201510750348.7A priority Critical patent/CN105285986A/en
Publication of CN102458156A publication Critical patent/CN102458156A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a health food or pharmaceutical composition for alleviating or suppressing pruritus, comprising chestnut shell extract as an active ingredient. In one example of the present invention, the chestnut shell extract comprised in the health food or pharmaceutical composition of the present invention can suitably be used as the active ingredient of a health food or pharmaceutical composition for alleviating or suppressing pruritus as it has been confirmed that it can exhibit an outstanding effect in alleviating or suppressing pruritus by suppressing the activity of proteinase-activated receptor-2 (PAR-2) which is a source of stimulation in pruritus.

Description

The healthy food or the pharmaceutical compositions that contain the chestnut bark extract
Technical field
The present invention relates to contain the healthy food or the pharmaceutical compositions of chestnut bark extract.
Background technology
Itch is defined as the offending dermal sensation of bringing out the desire of wanting to scratch; As pain, sense of touch, cold or hot and so on physiological defence mechanism; In the time of in skin is exposed to from the destructive stimulus of outside, it is carried out cognition and plays the effect of protecting skin.
Pruritus is frequent a kind of in the common symptoms of performance in various skin disease or general disease; Actual conditions are; Acute pruritus due to nettle rash, the various side effects of pharmaceutical drugs can easily be cured, but the treatment of the chronic pruritus of severe of Biliary atresia, kidney trouble or atopic diseases and so on is very difficult.
Itch is brought out by multiple reasons such as inflammation, cancer, metabolic disease, infection, psychiatric department disease, drug administration or pressure; In nearest several studies result, clear and definite skin and peripheral nervous system and central nervous system organic be connected with to the reaction of the stimulation of bringing out itch, regulate closely related.
Recently, clear and definite specific sensory neurone and acceptor thereof reacts itch specifically, and having accepted itch is not the next state of pain; But as indivedual sensations of sensory nervous system; Think mutually different itch medium and acceptor thereof and multiple disease association (Steinhoff et al., Journal of Investigative Dermatology, 126 of bringing out itch; Pp1705-1718,2006).
In the experiment that is used for pruritus research up to now, mainly use histamine, but advocate below proposing; The chronic pruritus that is idiocrasy and so on is to be caused by histamine dependence path (pathway), not equal to be to be caused by the nerve reason, this is illustrated as pruritus not onset (the Stander et al. of what antihistamine to atopic diseases; Experimental Dermatology; 11, pp12-24,2002).
In addition, known the 1st generation antihistaminic be mainly used in the whole body administration, but have anti-parasympathetic effect and show sedation; As the 1st generation antihistaminic chlorpheniramine when the topical, can't suppress itch (Munday et al., the Dermatology of atopic dermatitis patients; 205, pp40-45,2002); Owing to have the danger of cutaneous anaphylaxis, therefore do not encourage atopic dermatitis is used local antihistaminic.As the antihistaminic Ebastine of the 2nd generation that does not have sedation, RMI 9918 with the active medicine (ketoconazole, erythromycin) of block cell pigment (cytochrome) P450 when taking; Sometimes cause cardiac arrhythmia (Hey et al.; Arzneimittelforschung, 46, pp159-163; 1996), cause relative side effect.
Therefore, press for exploitation at present, particularly to the chronic pruritus efficacious therapy medicine of idiocrasy and so at the effective simultaneously little and safe pruritus therapeutic agent of side effect.
Summary of the invention
Therefore, the objective of the invention is to solve technical task to be solved all the time.Particularly, the purpose of one embodiment of the present of invention provides the healthy food or the pharmaceutical compositions that are used to relax or suppress pruritus that contains the chestnut bark extract, healthy food or the pharmaceutical compositions that is used to improve the healthy food or the pharmaceutical compositions of skin barrier and is used to suppress immunity.
According to such purpose; One embodiment of the invention relates to and contains the healthy food or the pharmaceutical compositions that are used to relax or suppress pruritus of chestnut bark extract as active ingredient, and it had not only reduced side effect that pruritus curative in the past has, but also the effect that has excellent inhibition or relax pruritus.
One embodiment of the invention relates to and contains the healthy food or the pharmaceutical compositions that are used to improve skin barrier function of chestnut bark extract as active ingredient.
One embodiment of the invention relates to and contains the healthy food or the pharmaceutical compositions that are used to suppress immunity of chestnut bark extract as active ingredient.
One embodiment of the present of invention relate to and contain the healthy food or the pharmaceutical compositions that are used to improve or treat atopic dermatitis of chestnut bark extract as active ingredient.
Composition of the present invention contains the chestnut bark extract as active ingredient; Thereby can bring into play excellent pruritus as the activity of the protease active acceptor-2 (Proteinase-Activated Receptor-2:PAR-2) of itch stimulus through inhibition suppresses or alleviation effects; Not only can improve the skin barrier that brings out by pruritus significantly and destroy, but also can treat the immune hypersensitivity reaction that can become the reason of bringing out pruritus in essence ground through the immunosuppressive activity of chestnut bark extract.
Description of drawings
Fig. 1 is the active chart that suppresses the mensuration result of effect (trypsin treatment) of PAR-2 that the chestnut bark extract of one embodiment of the present of invention is shown.
Fig. 2 is the active chart that suppresses the mensuration result of effect (SLIGKV processing) of PAR-2 that the chestnut bark extract of one embodiment of the present of invention is shown.
Fig. 3 is the chestnut skin 1 that one embodiment of the present of invention are shown, the active chart that suppresses the mensuration result of effect (trypsase, SLIGKV handles) of the PAR-2 of 3-butanediol (BG) extract.
Fig. 4 is the chestnut skin 1 that one embodiment of the present of invention are shown, and the pruritus (trypsin treatment) of 3-butanediol (BG) extract suppresses the chart of effect.
Fig. 5 is the chestnut skin 1 that one embodiment of the present of invention are shown, and the pruritus of 3-butanediol (BG) extract (SLIGRL processing) suppresses the chart of effect.
Fig. 6 is the chart that pruritus (SLIGRL processing) that the chestnut skin ethanol extract of one embodiment of the present of invention is shown suppresses effect.
Fig. 7 is the chart that pruritus (SLIGRL processing) that the chestnut skin ethanol extract oral administration of one embodiment of the present of invention is shown suppresses effect.
Fig. 8 is the chart that chestnut bark extract that one embodiment of the present of invention are shown reduces the effect of TNF-α secretion.
Fig. 9 is the chart that chestnut bark extract that one embodiment of the present of invention are shown reduces the effect of IL-6 secretion.
Figure 10 is the chart that chestnut bark extract that one embodiment of the present of invention are shown reduces the effect of IL-1 α secretion.
Figure 11 is the chart that chestnut bark extract that one embodiment of the present of invention are shown reduces the effect of IL-8 secretion.
Figure 12 is the chart that chestnut bark extract that one embodiment of the present of invention are shown reduces the effect of GM-CSF secretion.
Figure 13 is the chart that chestnut bark extract that one embodiment of the present of invention are shown reduces the effect that trypsase and IL-6 due to the active peptide (SLIGKV) secrete.
Figure 14 is the chart that chestnut bark extract that one embodiment of the present of invention are shown reduces the effect that trypsase and IL-8 due to the active peptide (SLIGKV) secrete.
Figure 15 is the chart that chestnut bark extract that one embodiment of the present of invention are shown reduces the effect that trypsase and GM-CSF due to the active peptide (SLIGKV) secrete.
Figure 16 is mensuration result's the chart of skin moisture-keeping effect that the chestnut skin ethanol extract of one embodiment of the present of invention is shown.
Figure 17 is mensuration result's the chart of the hyperkeratotic effect of improvement that the chestnut skin ethanol extract of one embodiment of the present of invention is shown.
Figure 18 is the chart that the pruritus of chestnut skin ethanol extract in the NC/Nga model that one embodiment of the invention is shown improves the mensuration result of effect.
Figure 19 is the chart that the IgE of chestnut skin ethanol extract in the NC/Nga model that one embodiment of the invention is shown reduces the mensuration result of effect.
Figure 20 is the active chart that suppresses the mensuration result of effect of PAR-2 that endothelium (tender skin) that the chestnut of one embodiment of the present of invention is shown and crust (shell) extract cause.
The specific embodiment
The present invention relates to contain the healthy food or the pharmaceutical compositions that are used to relax or suppress pruritus of chestnut bark extract as active ingredient.Present inventors etc. are with the target of protease active acceptor-2 (Proteinase-Activated Receptor-2:PAR-2) as the pruritus treatment; Measure the active degree that suppresses of PAR-2 that the chestnut bark extract causes; The result as after state confirm among the embodiment; Confirmed to demonstrate excellent PAR-2 antagonism in vitro, in addition, suppressed in the experiment as the SLIGRL that makes the peptide of PAR-2 activation specifically, SLIGKV or as the itch that the trypsase (Trypsin) of protease brings out; Confirmed to suppress significantly the activity of PAR-2, shown that very excellent itch suppresses effect.
Above-mentioned pruritus also is called as pruritus; The not special restriction of the induced factor of this pruritus or form; For example, bring out by in the dermatitis that comprises struvite dermatitis, atopic dermatitis, skin dermatitis, prickly heat, ulcer, frostbite, contact dermatitis, seborrhea, psoriasis and the parapsoriasis due to chapping more than one.
Under the situation of pruritus, can wipe, scratch skin constantly owing to the continuity itch or pinch.Thus; Bring out the secondary property skin injuries such as ulcer, scratch, lichen, pruigo, hyperpigmentation or pigmentation minimizing of skin; The various materials of inflammatory reaction in the skin are induced in secretion, and such secretion increases itch once more, and form the circulation of itch-scratch.
But contained chestnut bark extract shows that effective skin barrier function improves effect in healthy food of the present invention or the pharmaceutical compositions, and the result can effectively prevent or treat the secondary property skin injury that itch is brought out.
Above-mentioned composition thus, can improve skin barrier significantly to for example showing significant effect aspect the skin barrier restoring force by 2 property skin injury that produces from the itch of atopic dermatitis relaxing the skin barrier damage or improve.
Particularly; Above-mentioned composition can be through promoting skin moisture-keeping, preventing that Keratoderma from excessively improving skin barrier; As through after state embodiment confirms; The allergic model that utilizations such as present inventor are handled with
Figure BDA0000135370540000051
oxazolone (oxazolon) hairless mouse (Hairless mice) experimentizes; Mensuration is through epidermis moisture loss (transepidermal water loss; TEWL) and skin thickness (skin thickness), results verification the chestnut bark extract show and effectively promote skin moisture-keeping or prevent its hyperkeratotic effect.
And then, the present invention relates to contain the healthy food or the pharmaceutical compositions that are used to suppress immunity of chestnut bark extract as active ingredient.Above-mentioned composition can be healthy food or the pharmaceutical compositions that is used to treat for example idiocrasy, rheumatoid arthritis (rheumatoid arthritis) or Crohn disease (Crohn ' s disease); Wherein, can be to be used to prevent or treat composition as the atopic diseases of immune hypersensitivity reaction.
At atopic diseases from acute phase that skin injury etc. causes during to the chronic disease stage development; Observe the variation of the multiple secretor state of immune mediator; But in the patient's who suffers from atopic diseases injured skin, the increase that becomes of the concentration of most interleukins (Interleukin).In addition, granulocyte-macrophage colony stimutaing factor (GM-CSF) is known in atopical skin disease patient's injured skin, and its secretory volume increases; Cause chronic inflammatory reaction; And unbalanced (Matsubara et al., FEBS Letters, 566 that can cause idiocrasy patient immune system; Pp195-200,2004).
Relevant therewith; TNF-α), the expression of interleukin-6 (IL-6), interleukin 1 α (IL-1 α), interleukin 8 (IL-8) or granulocyte-macrophage colony stimutaing factor (Granulocyte-Macrophage Colony Stimulating Factor:GM-CSF) present inventors etc. have confirmed can significantly to reduce the tumor necrosis factor-alpha relevant with immune hypersensitivity reaction by the chestnut bark extract, and (Tumor Necrosis Factor-α:, the chestnut bark extract is suitable for as the healthy food that is used to suppress immune or the active ingredient of pharmaceutical compositions as a result.
Particularly, the present invention contains the chestnut bark extract as active ingredient, is suitable for improving or treating the active ingredient of the cosmetic combination of atopic dermatitis.
In addition, above-mentioned interleukin-6 (IL-6) and interleukin 8 (IL-8) also by known be the factor of in atopic diseases, bringing out itch, the chestnut bark extract can be used to effectively to prevent and treat the pruritus prevention from atopic diseases.
Above-mentioned chestnut skin is meant the dark brown skin that covers chestnut tree fruit, and the chestnut bark extract that uses in this specification is meant more than one the extract in the endothelium (tender skin) that is selected from chestnut, crust and composition thereof.
Above-mentioned chestnut micromicro is to be the skin from the chestnut of arbitrary kind; Not special restriction; For example can be to be selected from chestnut (Castanea crenata S.et Z.; Castanea mollissima Bl., Castanea bulgaris), the skin of the chestnut of more than one in Chinese chestnut (Castanea Bungeana Bl.) and the Korea chestnut (Castanea crenata for.multicarpa (Uyeki) Chung).As the chestnut skin, can use the endothelium (tender skin) of chestnut, also can use the crust (shell) of chestnut, but confirm especially in the group of chestnut crust (shell) extract-treated, to present excellent PAR-2 antagonism.
The not special restriction of the method for distilling of above-mentioned chestnut bark extract can be 1～4 lower alcohol, 1 through being selected from water, carbon number for example, and more than one solvents in 3-butanediol and the mixed solvent thereof extract; Above-mentioned solvent for example can be to be selected from water, methyl alcohol, ethanol, 1, more than one in 3-butanediol, butanols and composition thereof, for example; Above-mentioned chestnut bark extract can be by 1 of 10～100% alcohol solution or 10～100%, and the 3-butanediol extracts, particularly; Can be the chestnut skin 20～90% ethanol water solution extracts or 10～70% 1; 3-butanediol extract, more specifically, can be the chestnut skin 40～90% ethanol water solution extracts or 10～50% 1; 3-butanediol extract; Further particularly, can be the chestnut skin 60～90% ethanol water solution extracts or 20～40% 1,3-butanediol extract.
The not special restriction of the content of contained chestnut bark extract in the above-mentioned composition, but be benchmark with the gross weight of composition, can contain with the content of 0.005～80 weight %, preferably can contain with 0.01～30 weight %.If the content of above-mentioned chestnut bark extract is very few, then effect becomes very little, if too much, then the stability of formulation can step-down.
According to circumstances, in order to relax or to suppress pruritus, improve skin barrier and suppress immunity, the chestnut bark extract also can with antihistaminic, steroid dose, local anesthetic, immunodepressant in one or more material and use.
In the past; The technology that is used to relax atopic dermatitis and pruritus is to take antihistaminic, anabolic agent is coated with as the external application agent; Even but these preparations have and present the such shortcoming of the also very fast recurrence of temporary transient result of treatment; And then, reported side effects such as nervous centralis obstacle when taking these medicines, digestive organs obstacle.As the anabolic agent of cortex hormone of aadrenaline because antiinflammation efficiently and immunosuppressive action and effect is excellent; But side effect is also serious; Reported as the tacrolimus hydrate ointment of immunodepressant effectively, but possibly bring out cutaneum carcinoma, brought out the kidney obstacle when perhaps absorbing in the body in a large number at the skin injury position to the treatment of atopic dermatitis; Actual conditions are aspect security, to consider, are difficult to long-term use.
Therefore; To contain the chestnut bark extract as in the composition of active ingredient and antihistaminic, steroid dose, local anesthetic, the immunodepressant one or more suitably and the time spent, can be to the mitigation or the inhibition of pruritus, skin barrier improves and immunosupress etc. show significant effect safely without side effect.
Above-mentioned pharmaceutical compositions can also further contain anticorrisive agent, stabilizing agent, hydrating agents or emulsification promoter, be used to regulate pharmaceutic adjuvant and other useful materials in treatment such as salt and/or buffer of osmotic pressure; Except commonly used inorganic or the organic carrier; Can also carry out oral administration with solid, semisolid or aqueous form; Perhaps with non-oral, rectum, part, in skin, intravenous, muscle, in the abdominal cavity, subcutaneous etc. carry out administration, special preferred oral administration.
Above-mentioned oral Preparation has for example tablet, pill, hard and soft balsam wafer, liquid preparation, suspending agent, emulsion, syrup, granule etc., and these formulations can also contain diluent (example: lactose, glucose, sucrose, sweet mellow wine, D-sorbite, cellulose and glycine), lubricant (example: silica, talcum, stearic acid and magnesium thereof or calcium salt and polyethylene glycol) except active ingredient.Tablet can also contain the bond of Magnesiumaluminumsilicate, gelatinized corn starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone and so on; The pharmacy additives such as disintegrant, absorbent, colouring agent, flavouring agent and sweetener that according to circumstances, can contain starch, agar, alginic acid or its sodium salt and so on.Above-mentioned tablet can prepare through common mixing, granulating or coating process.
In addition, above-mentioned non-oral administration agent for example can be a skin preparations for extenal use, can be the formulation of lotion, ointment, gel, frost, patch or spray also, but be not limited to these.
The not special formulation that limits of above-mentioned health food composition for example can be processed tablet, granule, potus, molasses, meal rod formulations such as (diet bar).Health food composition to each formulation; Except active ingredient; Those skilled in the art can have no difficulty ground with the normally used composition in this field according to formulation or application target and suitably selected the cooperation, under the situation about using simultaneously with other raw material, can play synergy.
The dosage of above-mentioned active ingredient fixes in those skilled in the art's the level really; Administration consumption on the 1st of medicine is different and different according to multiple factors such as the progress degree of object to be administered, morbidity period, age, health status, complication; But if be benchmark with adult; Then generally can be with above-mentioned composition 1～500mg/kg, be preferably 30～200mg/kg and be divided into 1～2 time according to 1 day and carry out administration, no matter above-mentioned dosage does not limit scope of the present invention with any method yet.
Below, through embodiment further explain the present invention, but following embodiment is used for illustration the present invention, scope of the present invention not limit by them.
The preparation of [embodiment 1] chestnut bark extract
1-1) the chestnut skin 1, the preparation of 3-butanediol extract
Utilize 30% 1,3-butanediol (1,3-buthylene glyco1) at room temperature leached the chestnut skin 3 days.Then, the filter with 250 orders, 3 μ m, 1 μ m, 0.5 μ m size filters successively.Then, after 3 days, filter successively, obtain chestnut skin 1,3-butanediol extract with 0.5 μ m, 0.3 μ m, the big or small filter of 0.2 μ m in 0～4 ℃ of held (Standing).
1-2) the preparation of chestnut skin ethanol extract
Utilize 70% ethanol, the chestnut skin was at room temperature leached 3 days.Then, the filter with 250 orders, 3 μ m, 1 μ m, 0.5 μ m, 0.3 μ m, 0.2 μ m size filters successively.Then, behind 60 ℃ of following concentrated solutions,, obtain the chestnut skin ethanol extract of powder morphology 30 ℃ of vacuum drying of implementing 18 hours down.
The active inhibition of the PAR-2 of [Test Example 1] chestnut skin ethanol extract effect (external, trypsin treatment, HEK: people's epidermal keratinocyte)
The experiment the previous day, with keratinocyte (cell line name: HaCaT, obtain the place: ATCC) in the plate of 96 holes (well) to become 4 * 10 4The mode of cells/well is carried out plant division, then at 37 ℃, 5%CO 2Incubator (incubator) in cultivated 24 hours.After 24 hours; With 96 orifice plates with HBSS (Hanks ' Balanced Salt solution) buffer solution for cleaning (washing) 2 times after; Reaction buffer (reaction buffer:2uM Fluo-4-AM, 20%Pluronic acid, 2.5mM probenecid) is added in the cell.At 37 ℃, 5%CO 2Incubator (incubator) in the reaction 30 minutes; After at room temperature reacting 30 minutes; With HBSS buffer solution for cleaning (washing) 2 times, chestnut skin ethanol extract is handled with the concentration pair cell of 1ppm, 2ppm, 5ppm, 10ppm, 20ppm, 30ppm and 50ppm respectively.React after 10 minutes, (Trypsin) handles with 2U/ml trypsase, measures the interior Ca of cell in 80 seconds 2+Change in concentration.Ca in the cell 2+The mensuration of change in concentration is utilized FlexStation 3 (molecular device, the U.S.).After chestnut skin ethanol extract and trypsase (Trypsin) processing; Obtain the flexing (flex) of measuring for 80 seconds and after the difference of minimum of a value in the value that obtains and maximum, will be worth and the difference of minimum of a value during trypsase (Trypsin) processing and maximum compares and obtains inhibiting rate.
With reference to Fig. 1; Can confirm to utilize trypsase to make under the situation of PAR-2 activation in the terminal cutting filament propylhomoserin sequence (sequence) of the N-of PAR-2, calcium ion flows in the cell, but under the situation of the group that the chestnut bark extract is handled; The PAR-2 activation is suppressed, and the inflow of calcium ion significantly reduces.
(external, SLIGKV handles the active inhibition of the PAR-2 of [Test Example 2] chestnut skin ethanol extract effect, HEK: people's epidermal keratinocyte)
The experiment the previous day, with keratinocyte (cell line name: HaCaT, obtain the place: ATCC) in the plate of 96 holes (well) to become 4 * 10 4The mode of cells/well is carried out plant division, then at 37 ℃, 5%CO 2Incubator (incubator) in cultivated 24 hours.After 24 hours; With 96 orifice plates with HBSS (Hanks ' Balanced Salt solution) buffer solution for cleaning (washing) 2 times after; Reaction buffer (reaction buffer:2uM Fluo-4-AM, 20%Pluronic acid, 2.5mM probenecid) is added in the cell.At 37 ℃, 5%CO 2Incubator (incubator) in the reaction 30 minutes; After at room temperature reacting 30 minutes; With HBSS buffer solution for cleaning (washing) 2 times, chestnut skin ethanol extract is handled with the concentration pair cell of 1ppm, 2ppm, 5ppm, 10ppm, 20ppm, 30ppm and 50ppm respectively.React after 10 minutes, handle, measure the interior Ca of cell in 80 seconds with 5uMPAR-AP (SLIGKV) 2+Change in concentration.Ca in the cell 2+The mensuration of change in concentration is utilized FlexStation 3 (molecular device, the U.S.).After chestnut skin ethanol extract and 5uM PAR-AP (SLIGKV) processing; Obtain the flexing (flex) of measuring for 80 seconds and after the difference of minimum of a value in the value that obtains and maximum, will be worth and the difference of minimum of a value during 5uM PAR-AP (SLIGKV) processing and maximum compares and obtains inhibiting rate.
With reference to Fig. 2; Can confirm then to flow into calcium ion in the cell if the SLIGKV (people) that belongs to the activation peptide plays a role and makes the PAR-2 activation as direct part, but under the situation of the group that the chestnut bark extract is handled; The PAR-2 activation is suppressed, and the inflow of calcium ion significantly reduces.
[Test Example 3] chestnut skin 1, (external, SLIGKV handles the active inhibition of the PAR-2 of 3-butanediol (BG) extract effect, HEK: people's epidermal keratinocyte)
The experiment the previous day, with keratinocyte (cell line name: HaCaT, obtain the place: ATCC) in the plate of 96 holes (well) to become 4 * 10 4The mode of cells/well is carried out plant division, then at 37 ℃, 5%CO 2Incubator (incubator) in cultivated 24 hours.After 24 hours; With 96 orifice plates with HBSS (Hanks ' Balanced Salt solution) buffer solution for cleaning (washing) 2 times after; Reaction buffer (reaction buffer:2uM Fluo-4-AM, 20%Pluronic acid, 2.5mM probenecid) is added in the cell.At 37 ℃, 5%CO 2Incubator (incubator) in the reaction 30 minutes; After at room temperature reacting 30 minutes; With HBSS buffer solution for cleaning (washing) 2 times, with chestnut skin 1,3-butanediol (BG) extract is handled with the concentration pair cell of 0.1w/v%, 0.5w/v% and 1w/v% respectively.React after 10 minutes, handle, measure the interior Ca of cell in 80 seconds with 2U/ml trypsase (Trypsin) or 5uM PAR-AP (SLIGKV) 2+Change in concentration.Ca in the cell 2+The mensuration of change in concentration utilize FlexStation 3 (Molecular Device, USA).Through chestnut skin 1; After 3-butanediol (BG) extract and 2U/ml trypsase (Trypsin) or 5uM PAR-AP (SLIGKV) handle; Obtain the flexing (flex) of measuring for 80 seconds and after the difference of minimum of a value in the value that obtains and maximum, will be worth and the difference of minimum of a value when 2U/ml trypsase or 5uM PAR-AP (SLIGKV) processing and maximum compares and obtains inhibiting rate.
With reference to Fig. 3, the inflow that can confirm the intracellular calcium that trypsase or PAR-2 active peptide (SLIGKV) cause uprises along with the concentration of chestnut bark extract and significantly reduces.
[Test Example 4] chestnut skin 1,3-butanediol (BG) extract is to the inhibition effect of the pruritus that brought out by trypsase
Observe in hairless mouse (Hairless mice); With chestnut skin 1; 3-butanediol (BG) extract (in the PBS buffer solution) injects with the concentration of 1w/v%, 10w/v% and 20w/v% respectively simultaneously, and makes the behavioral trait of scratching (scratching behavior) due to intracutaneous (ID) injection trypsase (in the PBS buffer solution) the 200 μ g/ positions be able to suppress by concentration.Each measured value is represented with the percentage change of measuring mean value with respect to 2 baselines (Baseline), its result is shown in Fig. 4.
With reference to Fig. 4,1,3-butanediol (BG; Carrier) disposal group and 1% chestnut skin 1; 3-butanediol (BG) extract disposal group is observed the effect that does not have to suppress the itch of being brought out by trypsase; But at 10%, 20% chestnut skin 1, it is very big to observe the inhibition effect in 3-butanediol (BG) the extract disposal group.
[Test Example 5] chestnut skin 1,3-butanediol (BG) extract is to the inhibition effect of the itch of being brought out by SLIGRL
Observation is in hairless mouse (Hairless mice); With chestnut skin 1; 3-butanediol (BG) extract (in the PBS buffer solution) injects with 1%, 10% and 20% concentration respectively simultaneously; And make the behavioral trait of scratching (scratching behavior) due to intracutaneous (ID) injection SLIGRL (mouse PAR-2 active peptide is in the PBS buffer solution) the 50 μ g/ positions be able to suppress by concentration.Each measured value is used with respect to the percentage change of 2 baselines (Baseline) mensuration mean value and is represented, its result is shown in Fig. 5.
With reference to Fig. 5; Can observe from 1% chestnut skin 1,3-butanediol (BG) extract disposal group begins to 10%, 20% chestnut skin 1,3-butanediol (BG) extract disposal group; Along with the concentration increase of chestnut bark extract, the degree that the itch of being brought out by SLIGRL is able to suppress increases.
The effect of the pruritus that the inhibition that the coating of the skin of [Test Example 6] chestnut skin ethanol extract causes is brought out by SLIGRL
The chestnut bark extract that each test group is carried out the skin coated all is to be dissolved in water, ethanol, 1; In the solution that 3 butanediols mix with 5: 3: 2 ratio and use, experimental concentration be with the chestnut skin ethanol extract of powder morphology with 1,3 and the concentration of 10w/v% use.Carrier (vehicle) group is used the preparation that does not add the extract of embodiment 1 and make; As the itch evocating substance; PAR-2 active peptide (Activating Peptide (SLIGRL is from the peptide of rodent)) is dissolved in the PBS buffer solution, carries out intracutaneous injection with the concentration at 50 μ g/ places.
Get each sample 200 μ l of chestnut skin ethanol extract, handle with the mode that extensively stretches coating at the position, back of hairless mouse.Be divided into the morning and afternoon, 1 day 2 times, handled 4 days, in the 5th day the morning, before 30 minutes, carry out last processing in the injection of itch evocating substance.
For having or not of the increase of itch due to the itch evocating substance (PAR-2 active peptide, SLIGRL) relatively and itch minimizing that chestnut skin ethanol extract causes; The skin of measuring chestnut skin ethanol extract is coated with preceding 2 days each number of times of scratching of measuring 40 minutes; Value that 2 days mean value of calculating is obtained and stimulus inject the back 40 minutes number of times of scratching and compare, and use the percentage change value representation.
The experiment of itch from hairless mouse injection itch evocating substance packed into before 20 minutes observe with transparent hurdle and give 20 minutes adaptation times and begin.When adaptation time finishes, with itch evocating substance (PAR-2 active peptide; SLIGRL) skin to the position, back of the test hairless mouse that adapt to finish carries out intracutaneous injection (intradermal injection).When injection finishes, directly hairless mouse is packed into once more and observe, measure 40 minutes hind leg and scratch and inject the number of times at the position that the itch evocating substance is arranged with after in the hurdle.To scratch or the behavior that catches in its mouth forecloses with front foot, only will measure as the index of itch behavior with the scratch behavior of injection site of metapedes.
With reference to Fig. 6; After can confirming chestnut skin ethanol extract (Chestnut Inner Bark Extract) coated skin; When the concentration that is 10%, even do not giving under the common state that stimulates with itch, the number of times of scratching also reduces; Giving under the situation about stimulating, reducing since the 1% concentration number of times of scratching with itch.
The effect of the pruritus that the inhibition that the oral administration of [Test Example 7] chestnut skin ethanol extract causes is brought out by SLIGRL
The extract that obtains among the embodiment 1 is carried out oral administration to the female hairless mouse (Hariless mice) in 8 ages in week, observe itch and suppress effect.
Each test group is carried out that chestnut bark extract that oral administration handles all mixes with distilled water and as the suspension use, experimental concentration be with the chestnut skin ethanol extract of powder morphology respectively with 200 and the concentration of 500mg/Kg carry out oral administration.Carrier (vehicle) group is not added the extract of embodiment 1 and is used pure distilled water; As the itch evocating substance; PAR-2 active peptide (Activating Peptide (SLIGRL is from the peptide of rodent)) is dissolved in the PBS buffer solution, carries out intracutaneous injection with the concentration at 50 μ g/ places.
Oral administration is the said sample of getting appropriate amount, with 1 administration on the 1st 5 days, in the 5th day the morning, before 30 minutes, carries out last administration in the injection of itch evocating substance.
For having or not of the increase of itch due to the itch evocating substance (PAR-2 active peptide, SLIGRL) relatively and itch minimizing that chestnut skin ethanol extract oral administration causes; Measure preceding 2 days each number of times of scratching of measuring 40 minutes of oral administration of chestnut skin ethanol extract; Value that 2 days mean value of calculating is obtained and stimulus inject the back 40 minutes number of times of scratching and compare, and use the percentage change value representation.
Itch experiment from hairless mouse injection itch evocating substance packed into before 20 minutes observe with transparent hurdle and give 20 minutes adaptation times and begin.After adaptation time finishes, with itch evocating substance (PAR-2 active peptide; SLIGRL) skin to the position, back of the test hairless mouse that adapt to finish carries out intracutaneous injection (intradermal injection).After injection finishes, directly hairless mouse is packed into once more and observe, measure 40 minutes scratch and inject the number of times at the position that the itch evocating substance is arranged with hind leg with after in the hurdle.To scratch or the behavior that catches in its mouth forecloses with front foot, only will measure as the index of itch behavior with the scratch behavior of injection site of metapedes.
With reference to Fig. 7, after can confirming chestnut skin ethanol extract carried out oral administration, the chestnut skin reduces with concentration the inhibition effect that itch stimulates.
[Test Example 8] chestnut bark extract causes the secretion of TNF-α to reduce
Test the previous day, with Keratoderma epithelial cell (Normal human skin keratinocyte, NHEK, distributors: Lonza) to become 5 * 10 4The mode of cells/well is carried out plant division in the plate of 96 holes (well), then at 37 ℃, 5%CO 2Incubator (incubator) in cultivated 24 hours.After 24 hours, clean 2 cells, change serum-free KBM (serum free KBM (keratinocyte hosqt media)) into PBS.Each hole (well) handled (10,25,50ppm) through the chestnut skin by concentration, react after 30 minutes, use PGSA (10,50ppm), LPS (1ppm) to handle respectively.At 37 ℃, 5%CO 2Incubator (incubator) in cultivate after 24 hours, take out nutrient solution, carry out ELISA to TNF-α.ELISA utilizes the experimental technique of manufacturing company (BD science).
With reference to Fig. 8, can observe the chestnut skin TNF-α secretion that increases because of PGSA and LPS is significantly reduced.
[Test Example 9] chestnut bark extract causes the secretion of IL-6 to reduce
Carry out ELISA, in addition, utilize the method identical in fact with Test Example 8 to IL-6.
With reference to Fig. 9, can observe the chestnut skin and make the IL-6 secretion that increases because of PGSA and LPS obtain the inhibition of great disparity.
[Test Example 10] chestnut bark extract causes the secretion of IL-1 α to reduce
Carry out ELISA, in addition, utilize the method identical in fact with Test Example 8 to IL-1 α.
With reference to Figure 10, can observe the chestnut skin and the IL-1 α secretory volume that increases because of PGSA and LPS increased with concentration reduce.
[Test Example 11] chestnut bark extract causes the secretion of IL-8 to reduce
Carry out ELISA, in addition, utilize the method identical in fact with Test Example 8 to IL-8.
With reference to Figure 11, can observe the chestnut skin IL-8 secretion that increases because of PGSA and LPS is significantly reduced.
[Test Example 12] chestnut bark extract causes the secretion of GM-CSF to reduce
Carry out ELISA, in addition, utilize the method identical in fact with Test Example 8 to GM-CSF.
With reference to Figure 12, can observe along with the concentration of chestnut skin increases the amount minimizing of the GM-CSF that secretes because of PGSA and LPS.
[Test Example 13] chestnut bark extract is to the inhibition effect of IL-6 secretion due to trypsase and the active peptide (SLIGKV)
Test the previous day, (Normal human skin keratinocyte, NHEK obtain the place: Lonza) to become 5 * 10 with the Keratoderma epithelial cell 4The mode of cells/well is carried out plant division in the plate of 96 holes (well), then at 37 ℃, 5%CO 2Incubator (incubator) in cultivated 24 hours.After 24 hours, clean 2 cells, change serum-free KBM (serum free KBM (keratinocyte hosqt media)) into PBS.With the chestnut bark extract each hole (well) handled (10,50ppm) by concentration, react after 30 minutes, (SLIGKV 50uM) handles to use trypsase (10nM) or PAR-2 activation peptide respectively.At 37 ℃, 5%CO 2Incubator (incubator) in cultivate after 24 hours, take out nutrient solution, carry out ELISA to IL-6.ELISA utilizes the experimental technique of manufacturing company (BD science).
With reference to Figure 13, can observe the IL-6 secretion that chestnut bark extract concentration dependent ground inhibition trypsase and active peptide (SLIGKV) cause.
[Test Example 14] chestnut bark extract is to the inhibition effect of IL-8 secretion due to trypsase and the active peptide (SLIGKV)
Carry out ELISA, in addition, utilize the method identical in fact with Test Example 13 to IL-8.
With reference to Figure 14, can observe the IL-8 secretion that chestnut bark extract concentration dependent ground inhibition trypsase and active peptide (SLIGKV) cause.
[Test Example 15] chestnut bark extract is to the inhibition effect of GM-CSF secretion due to trypsase and the active peptide (SLIGKV)
Carry out ELISA, in addition, utilize the method identical in fact with Test Example 13 to GM-CSF.
With reference to Figure 15, can observe the GM-CSF secretion that chestnut bark extract concentration dependent ground inhibition trypsase and active peptide (SLIGKV) cause.
[Test Example 16] measured the skin moisture-keeping effect of chestnut skin ethanol extract
Estimate the skin barrier function recovery capability of the chestnut skin ethanol extract of embodiment 1 to long-time skin injury.At first; Be born after the young hairless mouse (Orient in 7～8 weeks; Korea S) back (back) is coated with 1 time oxazolone (oxazolone) every day; Periodically be coated with 6 days, the skin barrier of animal used as test is sustained damage.Then, measure with atmidometer (Delfin, Finland) and to divide loss amount (Transepidermal Water Loss:TEWL), will have and per hour show 50g/m through the severe edema due to hypofunction of the spleen 2Abovely divide the animal used as test of the skin of loss to divide into groups through the severe edema due to hypofunction of the spleen, with 1 with the chestnut bark extract of 5w/v% respectively with every 5cm 2Skin area is the capacity of 100 μ l, every day 2 times, be coated with 10 days continuously after, the determination experiment animal divide loss amount (TEWL) through the severe edema due to hypofunction of the spleen, its result is shown in Figure 16.
Shown in figure 16; Can know in the allergic model (Allergy model) that hairless mouse is carried out the processing of
Figure BDA0000135370540000152
oxazolone; Through coating chestnut bark extract; The barrier function that divides loss amount to have the damage of making through the severe edema due to hypofunction of the spleen that the dermatitis (atopic dermatitis, atopic dermatitis) of being induced by
Figure BDA0000135370540000153
oxazolone is caused increase recovers and the function of getting back to normal skin.
[Test Example 17] measured chestnut skin ethanol extract and improved hyperkeratotic effect
In embodiment 1, estimate chestnut skin ethanol extract and improve the excessive effect of Keratoderma.At first; Be born after the young hairless mouse (Orient in 7～8 weeks; Korea S) back (back) is coated with 1 time
Figure BDA0000135370540000161
oxazolone (oxazolone) every day; Periodically be coated with 6 days, the skin barrier of animal used as test is sustained damage.Then, measure with atmidometer (Delfin, Finland) and to divide loss amount (Transepidermal Water Loss:TEWL), will have and per hour show 50g/m through the severe edema due to hypofunction of the spleen 2Abovely divide the animal used as test of the skin of loss to divide into groups through the severe edema due to hypofunction of the spleen, with substances with every 5cm 2Skin area is the capacity of 100 μ l, every day 2 times, be coated with 10 days continuously after; Pick up (twofold is measured, two-folding measurement) about the location of back (back), utilize micrometer (Mitsubishi; Japan) measure skin thickness, its result is shown in Figure 17.
With reference to Figure 17; Can confirm that through using the powder of chestnut bark extract the skin thickness that the dermatitis of being brought out by
Figure BDA0000135370540000162
oxazolone (oxazolon) is caused increase demonstrates and suppresses the excessive effect of Keratoderma.
[Test Example 18] measured chestnut skin ethanol extract and in the NC/Nga model, reduced IgE and the effect of improving pruritus
In embodiment 1, estimate the interior IgE minimizing of serum and the itch of chestnut skin ethanol extract with the NC/Nga mouse model and improve effect.At first, birth after the position, back (back) of the young NC/Nga mouse in 7～8 weeks utilizes shearing machine (clipper) to lose hair or feathers, is removed the gross profit of remnants with depilatory cream fully.To the position, back and the auricle position of exposing, Df (dust mite (dermatophagoides farinae)) 100mg is coated with in 3 weeks 4 times for 2 times with a week equably, and brings out atopic diseases.After the chestnut bark extract being divided into 100mg/kg and 250mg/kg 2 groups and carrying out administration in 3 weeks with week 5 times,, pack the NC/Nga mouse into observation with behind the hurdle, be determined between 2 hours with the scratch number of times at position, back of hind leg in order to measure pruritus.To scratch or the behavior that catches in its mouth forecloses with front foot, only will measure as the index of itch behavior with the behavior that metapedes is scratched.Being determined as from the blood sample separation of serum of taking a blood sample through the eye socket veniplex of SERUM IgE utilizes the Opt IgE kit (Opt IgE kit) of BD science (BD science) to implement ELISA and measure.Be illustrated in the 250mg/kg administration group itch among Figure 18 and compare minimizing,, can confirm the minimizing that in the administration group of 250mg/kg, shows IgE significantly with reference to Figure 19 with non-processed group.
(external, SLIGKV handles, HEK: people's epidermal keratinocyte) in the comparison of the active inhibition of the PAR-2 of [Test Example 19] chestnut crust ethanol extract and chestnut endothelium ethanol extract effect
The crust of chestnut is separated with endothelium and after the drying, according to embodiment 1-2) identical method prepares the outer bark extract of chestnut, in the chestnut bark extract also according to embodiment 1-2) identical method preparation.Use the active inhibition of the PAR-2 effect of measuring chestnut crust ethanol extract and chestnut endothelium ethanol extract with Test Example 2 identical methods, and be shown among below table 2 and Figure 20.
Table 2
Figure BDA0000135370540000171
(external, SLIGKV handles, HEK: people's epidermal keratinocyte) in the comparison of the active inhibition of the PAR-2 of [Test Example 20] chestnut crust ethanol extract and chestnut endothelium ethanol extract effect
The crust (shell) of chestnut is carried out the processing shown in below table 3 with the concentration of endothelium (tender skin) extract, in addition, according to measuring the active effect that suppresses of PAR-2 with Test Example 19 identical methods.
Table 3
Below, explain that the formulation of the present composition is routine, pharmaceutical compositions or health food composition can be applied to various formulations, and this does not really want to limit the present invention, and just will specify the present invention.
Ointment in [formulation example 1] skin preparations for extenal use
Composition according to below table 1 record prepares ointment with conventional method.
Table 1
Gradation composition Content (weight %)
Embodiment 1 0.1
Glycerine 3.0
Butanediol 2.0
Propane diols 2.0
Carboxyl ethylene polymer 0.1
The PEG-12 nonylplenyl ether 0.2
Polysorbate 80 0.4
Ethanol 10.0
Triethanolamine 0.1
Anticorrisive agent, pigment, spices In right amount
Purified water Surplus
The preparation of [formulation example 2] powder
Embodiment 1 ... 100mg
Lactose ... 100mg
Talcum ... 10mg
Grease ... 5mg
Mentioned component is mixed, be filled in the sealed packet and preparation powder.
The preparation of [formulation example 3] tablet
Embodiment 1 ... 50mg
Cornstarch ... 100mg
Lactose ... 100mg
Dolomol ... 2mg
Vitamin C ... 50mg
After mentioned component mixed, carry out compressing tablet according to the method for preparing tablet thereof of routine and prepare tablet.
The preparation of [formulation example 4] capsule
Embodiment 1 ... 50mg
Corn ... 100mg
Lactose ... 100mg
Dolomol ... 2mg
Vitamin C ... 50mg
Serine ... 50mg
Capsule preparation method thereof according to routine mixes mentioned component, is filled in the gelatine capsule and the preparation capsule.
The preparation of [formulation example 5] liquid preparation
Embodiment 1 ... 100mg
Isomerized sugar ... 10g
Sweet mellow wine ... 5g
Vitamin C ... 50mg
Serine ... 50mg
Grease ... In right amount
Purified water ... In right amount
Utilize conventional liquid preparation preparation method in purified water, to add various compositions and make it dissolving, add an amount of lemonene after, behind the mixing mentioned component; Add purified water, overall adjustment to 100ml, is filled in the brown bottle; Sterilize the preparation liquid preparation.
The preparation of [formulation example 6] healthy food
Embodiment 1 ... 1000mg
Vitamin mixtures
Retinyl acetate ... 70 μ g
Vitamin E ... 1.0mg
Vitamin B1 ... 0.13mg
Vitamin B2 ... 0.15mg
Vitamin B6 ... 0.5mg
Cobalamin ... 0.2 μ g
Vitamin C ... 10mg
Biotin ... 10 μ g
Niacinamide ... 1.7mg
Folic acid ... 50 μ g
Calcium pantothenate ... 0.5mg
The inanimate matter mixture
Ferrous sulfate ... 1.75mg
Zinc oxide ... 0.82mg
Magnesium carbonate ... 25.3mg
Potassium dihydrogen phosphate ... 15mg
Calcium monohydrogen phosphate ... 55mg
Potassium citrate ... 90mg
Calcium carbonate ... 100mg
Magnesium chloride ... 24.8mg
The ratio of components of the mixture of said vitamin and mineral matter is with preferred embodiment mixing composition with the composition that relatively is suitable for healthy food; But also can its match ratio be implemented modification arbitrarily; After can using conventional healthy food preparation method to mix mentioned component; The preparation particle utilizes conventional method to be used to prepare health food composition.
The preparation of [formulation example 7] healthy beverage
Embodiment 1 ... 1000mg
Citric acid ... 1000mg
Oligosaccharides ... 100g
The plum concentrate ... 2g
Taurine ... 1g
Overall after the adding purified water ... 900ml
After using conventional healthy beverage preparation method to mix mentioned component, after about 1 hour, filter the solution of processing 85 ℃ of following agitating heating, pack in 2 ℃ of containers of sterilization, after sealing was sterilized, stored refrigerated was used to prepare healthy beverage composition of the present invention then.
Ratio of components be with the composition that relatively is suitable for having a liking for beverage with preferred embodiment mixing composition, but also can be and its match ratio is carried out modification arbitrarily according to region such as demand stratum, demand country, use, national characteristic hobby degree.

Claims (15)

1. a healthy food or a pharmaceutical compositions that is used to relax or suppress pruritus wherein, contains the chestnut bark extract as active ingredient.
2. healthy food or the pharmaceutical compositions that is used to relax or suppress pruritus according to claim 1; Wherein, said composition relaxes or suppresses by the pruritus that brings out more than in the dermatitis that comprises struvite dermatitis, atopic dermatitis, skin dermatitis, prickly heat, ulcer, frostbite, contact dermatitis, seborrhea, psoriasis and the parapsoriasis due to chapping any.
3. healthy food or the pharmaceutical compositions that is used to relax or suppress pruritus according to claim 1, wherein, the pruritus that said composition relaxes or suppresses to be brought out by atopic dermatitis.
4. a healthy food or a pharmaceutical compositions that is used to improve skin barrier function wherein, contains the chestnut bark extract as active ingredient.
5. healthy food or the pharmaceutical compositions that is used to improve skin barrier according to claim 4, wherein, said composition is used to relax the restoring force of perhaps improving skin barrier from the skin barrier damage of atopic dermatitis.
6. healthy food or the pharmaceutical compositions that is used to improve skin barrier according to claim 4, wherein, said composition is used to promote skin moisture-keeping or prevents that Keratoderma is excessive.
7. a healthy food or a pharmaceutical compositions that is used to suppress immunity wherein, contains the chestnut bark extract as active ingredient.
8. healthy food or the pharmaceutical compositions that is used to suppress immunity according to claim 7, wherein, said composition is used for the prevention or the treatment of atopic diseases.
9. healthy food or the pharmaceutical compositions that is used to suppress immunity according to claim 7, wherein, said composition is used for atopic treatment.
10. a healthy food or a pharmaceutical compositions that is used to improve or treat atopic dermatitis wherein, contains the chestnut bark extract as active ingredient.
11., wherein, be benchmark, contain said chestnut bark extract with the content of 0.005～80 weight % with the gross weight of composition according to each described healthy food or pharmaceutical compositions in the claim 1～10.
12. according to each described healthy food or pharmaceutical compositions in the claim 1～10, wherein, said chestnut skin is more than one in endothelium, crust and their mixture that is selected from chestnut.
13. healthy food according to claim 12 or pharmaceutical compositions, wherein, said chestnut skin is the crust of chestnut, i.e. shell.
14. according to each described healthy food or pharmaceutical compositions in the claim 1～10; Wherein, Said chestnut bark extract is to be 1～4 lower alcohol, 1 through being selected from water, carbon number, and the solvent of more than one in 3-butanediol and their mixed solvent extracts.
15. healthy food according to claim 14 or pharmaceutical compositions, wherein, said chestnut bark extract is through being selected from water, methyl alcohol, ethanol, butanols, 1, and the solvent in 3-butanediol and their mixture extracts.
CN2010800359033A 2009-06-18 2010-06-18 Health food or pharmaceutical composition comprising chestnut shell extract Pending CN102458156A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510750348.7A CN105285986A (en) 2009-06-18 2010-06-18 Health food or pharmaceutical composition comprising chestnut shell extract

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0054579 2009-06-18
KR20090054579 2009-06-18
PCT/KR2010/003983 WO2010147440A2 (en) 2009-06-18 2010-06-18 Health food or pharmaceutical composition comprising chestnut shell extract

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510750348.7A Division CN105285986A (en) 2009-06-18 2010-06-18 Health food or pharmaceutical composition comprising chestnut shell extract

Publications (1)

Publication Number Publication Date
CN102458156A true CN102458156A (en) 2012-05-16

Family

ID=43356951

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800359033A Pending CN102458156A (en) 2009-06-18 2010-06-18 Health food or pharmaceutical composition comprising chestnut shell extract
CN201510750348.7A Pending CN105285986A (en) 2009-06-18 2010-06-18 Health food or pharmaceutical composition comprising chestnut shell extract

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510750348.7A Pending CN105285986A (en) 2009-06-18 2010-06-18 Health food or pharmaceutical composition comprising chestnut shell extract

Country Status (4)

Country Link
JP (1) JP2012530699A (en)
KR (1) KR101338681B1 (en)
CN (2) CN102458156A (en)
WO (1) WO2010147440A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104770644A (en) * 2015-04-29 2015-07-15 唐凯 Diabetes health care product based on affinal drugs and diet
CN107686451A (en) * 2017-09-29 2018-02-13 武汉华士特工业生物技术开发有限公司 A kind of chestnut peel method for preparing extractive containing ceramide
CN109562054A (en) * 2016-07-29 2019-04-02 株式会社莎提诗制药 Chestnut bark extract

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (en) 2009-09-09 2018-03-08 Regeneron Pharma High affinity human antibodies to human protease-activated receptor-2
KR101595959B1 (en) * 2013-02-18 2016-02-19 재단법인 대구테크노파크 Composition for preventing, improving or treating allergic dermatitis comprising hot water extract or ferment extract of chestnut inner shell
KR101643048B1 (en) * 2014-10-23 2016-07-27 단국대학교 천안캠퍼스 산학협력단 Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising castanea crenata inner shell extract
KR102165675B1 (en) 2018-10-17 2020-10-14 강진영 A cosmetic manufacturing method comprising an extract extracted from chestnuts or a peptide fraction isolated therefrom and natural caffeine derived from coffee
JP7263538B2 (en) * 2019-11-01 2023-04-24 株式会社 資生堂 Skin condition evaluation method using active PAR-2 in skin as index, screening method for PAR-2 activation promoter or inhibitor, and PAR-2 activation inhibitor
FR3124947A1 (en) * 2021-07-12 2023-01-13 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Ingestible composition (Ci) for use in the treatment of a skin disorder induced by an intestinal disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10226633A (en) * 1997-02-14 1998-08-25 Koreana Cosmetics Co Ltd Cosmetic composition containing extract of chestnut bur
CN101268847A (en) * 2007-03-23 2008-09-24 张宝林 Blood cleaning cola for eliminating sub-health
KR20080101821A (en) * 2008-08-27 2008-11-21 김선일 Cosmetic included to flos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH092960A (en) * 1995-06-15 1997-01-07 Watanabesan Shoten:Kk Dermatitis treating agent and treatment of dermatitis
JPH09175993A (en) * 1995-12-27 1997-07-08 Pairei:Kk Production of bathing agent
JPH09182574A (en) * 1996-01-05 1997-07-15 Pairei:Kk Production of chestnut tea
KR100308178B1 (en) * 1997-11-10 2002-02-28 유상옥,송운한 Skin wrinkle care composition containing chestnut bark extract
KR100376136B1 (en) * 1998-08-13 2003-06-18 주식회사 코리아나화장품 Astringent Cosmetic Composition Containing Yulpi Extract
KR20000065305A (en) * 1999-04-01 2000-11-15 유상옥 Skin care composition containing stabilized retinol, phytosphingosine, and Castaneae crenata extracts
AU7961900A (en) * 1999-10-29 2001-05-14 Kyowa Hakko Kogyo Co. Ltd. Skin texture-improving agents
KR20010092070A (en) * 2000-03-20 2001-10-24 유상옥,송운한 Skin elasticity-improving cosmetic composition comprising Chestnut inner bark extract and Malt extract
JP2002371276A (en) * 2001-06-14 2002-12-26 Kanebo Ltd Antioxidant, food and cosmetic obtained by using the same
JP3847649B2 (en) * 2002-04-01 2006-11-22 株式会社ノエビア Topical skin preparation
KR100483539B1 (en) * 2002-12-10 2005-04-18 이진형 Composition for preventing or treating atopic dermatitis and process for preparation thereof
JP4090861B2 (en) * 2002-12-13 2008-05-28 クラシエフーズ株式会社 Antioxidants, foods and cosmetics using the same
JP2005139070A (en) * 2003-11-04 2005-06-02 Kanebo Cosmetics Inc Skin cosmetic
KR20080090169A (en) * 2007-04-04 2008-10-08 (주) 아디포젠 Active extracts, containing scoparone, isolated from mugwort or chestnut peel having inhibitory effects on obesity
JP2008195936A (en) * 2008-01-28 2008-08-28 Kracie Foods Ltd Antioxidant and food and cosmetics using the same
KR101172114B1 (en) * 2008-11-17 2012-08-10 (주)아모레퍼시픽 Skin whitening cosmetic composition containing natural crop powders as exfoliation surface skin cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10226633A (en) * 1997-02-14 1998-08-25 Koreana Cosmetics Co Ltd Cosmetic composition containing extract of chestnut bur
CN101268847A (en) * 2007-03-23 2008-09-24 张宝林 Blood cleaning cola for eliminating sub-health
KR20080101821A (en) * 2008-08-27 2008-11-21 김선일 Cosmetic included to flos

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
何黎: "皮肤屏障与保湿", 《实用医院临床杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104770644A (en) * 2015-04-29 2015-07-15 唐凯 Diabetes health care product based on affinal drugs and diet
CN109562054A (en) * 2016-07-29 2019-04-02 株式会社莎提诗制药 Chestnut bark extract
CN109562054B (en) * 2016-07-29 2022-07-01 株式会社莎提诗制药 Chestnut skin extract
CN107686451A (en) * 2017-09-29 2018-02-13 武汉华士特工业生物技术开发有限公司 A kind of chestnut peel method for preparing extractive containing ceramide

Also Published As

Publication number Publication date
WO2010147440A3 (en) 2011-03-31
KR101338681B1 (en) 2013-12-09
CN105285986A (en) 2016-02-03
KR20120027432A (en) 2012-03-21
WO2010147440A2 (en) 2010-12-23
JP2012530699A (en) 2012-12-06

Similar Documents

Publication Publication Date Title
CN102458156A (en) Health food or pharmaceutical composition comprising chestnut shell extract
WO2008140200A1 (en) External compositions for the skin
CN100404054C (en) Decoction Chinese medicine sterilizing antiphlogistic, preparation and use thereof
US20150038568A1 (en) Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis
KR20070054222A (en) Medicine having analgesic effects
US20040258765A1 (en) Method for treatment of sores and lesions of the skin
WO2018137319A1 (en) Application of sarcococca vagans, chinese medicinal ointment for treating skin disease, preparation method and application thereof
CN108379350A (en) A kind of eczema ointment and preparation method thereof
CN102458356A (en) Cosmetic composition comprising chestnut shell extract
EP3884942B1 (en) Use of bulleyaconitine a for treating skin disorders
CN104161763B (en) A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema
CN108619486B (en) Ointment for treating skin diseases and preparation method thereof
CN114452229A (en) Skin care composition containing artemisinin
JP2023529202A (en) A composition for preventing, improving or treating allergic diseases or itching containing a pentapeptide as an active ingredient
US11344505B1 (en) Herbal formulations of carnivorous plants and methods for treating inflammation
CN110269926A (en) Middle benefit gas, which is relaxed, warms up composition and its preparation method and application
CN101234140B (en) Pharmaceutical composition for curing eczema and preparation and application thereof
CN101628067B (en) Medicament for treating diskal hernia and arthralgia
CA2567637A1 (en) Using organic and/or inorganic potassium and its salts to treat autoimmune and other health disorders and methods of administering the same
KR101567735B1 (en) Composition for preventing or improving or treating psoriasis comprising immunomodulating agent and glucosamine
KR20030092519A (en) Composition for improving or preventing of allergic dermatological diseases
CN113842405B (en) Application of broussonetia papyrifera root-bark extract in preparation of anti-allergic and itching-relieving medicine for skin
CN103735494B (en) External antipruritic ointment for treating mosquito bite and preparation method of external antipruritic ointment
KR101680012B1 (en) Composition for external application for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient
KR102248513B1 (en) A composition for preventing and treating athlete's foot

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120516